JP2006514920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514920A5 JP2006514920A5 JP2004538491A JP2004538491A JP2006514920A5 JP 2006514920 A5 JP2006514920 A5 JP 2006514920A5 JP 2004538491 A JP2004538491 A JP 2004538491A JP 2004538491 A JP2004538491 A JP 2004538491A JP 2006514920 A5 JP2006514920 A5 JP 2006514920A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- dsrna
- cells
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 31
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 21
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 12
- 108060003951 Immunoglobulin Proteins 0.000 claims 10
- 102000018358 immunoglobulin Human genes 0.000 claims 10
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 230000037361 pathway Effects 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 102000043129 MHC class I family Human genes 0.000 claims 4
- 108091054437 MHC class I family Proteins 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 3
- 101710132601 Capsid protein Proteins 0.000 claims 3
- 241000700721 Hepatitis B virus Species 0.000 claims 3
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 3
- 241000701806 Human papillomavirus Species 0.000 claims 3
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 102100034343 Integrase Human genes 0.000 claims 3
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 3
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 3
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims 3
- 108010055044 Tetanus Toxin Proteins 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000001605 fetal effect Effects 0.000 claims 3
- 108700012707 hepatitis C virus NS3 Proteins 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 208000023958 prostate neoplasm Diseases 0.000 claims 3
- 229940118376 tetanus toxin Drugs 0.000 claims 3
- 241000712461 unidentified influenza virus Species 0.000 claims 3
- 102000007298 Mucin-1 Human genes 0.000 claims 2
- 108010008707 Mucin-1 Proteins 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 210000000447 Th1 cell Anatomy 0.000 claims 1
- 210000004241 Th2 cell Anatomy 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41221902P | 2002-09-20 | 2002-09-20 | |
| PCT/US2003/007995 WO2003078595A2 (en) | 2002-03-15 | 2003-03-14 | Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response |
| PCT/US2003/030188 WO2004027049A2 (en) | 2002-09-20 | 2003-09-18 | Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514920A JP2006514920A (ja) | 2006-05-18 |
| JP2006514920A5 true JP2006514920A5 (https=) | 2006-11-02 |
Family
ID=32030833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004538491A Pending JP2006514920A (ja) | 2002-09-20 | 2003-09-18 | 抗原提示細胞の選択サブセットの同時ローディング／活性化によりｔ細胞のエフェクタープロファイルを発生させ制御するための方法及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20060193855A1 (https=) |
| EP (2) | EP2258712A3 (https=) |
| JP (1) | JP2006514920A (https=) |
| CN (1) | CN1703427A (https=) |
| AT (1) | ATE460944T1 (https=) |
| AU (1) | AU2003276932A1 (https=) |
| CA (1) | CA2499066A1 (https=) |
| DE (1) | DE60331741D1 (https=) |
| WO (1) | WO2004027049A2 (https=) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2258712A3 (en) | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| WO2007022477A2 (en) * | 2005-08-17 | 2007-02-22 | Multicell Immunotherapeutics, Inc. | Methods and compositions to generate and control the effector profile of t cells |
| CN101330928B (zh) * | 2005-10-07 | 2012-11-14 | 西马生物医学计划公司 | 用于预防和治疗丙型肝炎的免疫刺激剂组合 |
| CA2730742C (en) * | 2008-07-16 | 2017-05-23 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| CA2809819A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| BR112012030311A2 (pt) | 2010-06-08 | 2017-01-24 | Genentech Inc | anticorpo |
| JP5975399B2 (ja) * | 2010-08-30 | 2016-08-23 | 国立研究開発法人理化学研究所 | ＴＧＦ−β受容体の活性化を抑制する活性を有する化合物、そのスクリーニング方法、並びにＣ型肝炎ウィルスに起因する疾患の予防又は治療のための組成物 |
| JP5889912B2 (ja) | 2010-11-17 | 2016-03-22 | ジェネンテック， インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
| KR101992502B1 (ko) | 2011-05-12 | 2019-06-24 | 제넨테크, 인크. | 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법 |
| CN102336821B (zh) * | 2011-08-11 | 2014-10-15 | 北京永泰免疫应用科技有限公司 | Melan-A表位肽及其在预防和/或治疗肿瘤中的用途 |
| JP6104257B2 (ja) | 2011-10-14 | 2017-03-29 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピンおよびそのコンジュゲート |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| US10751346B2 (en) | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
| ES2649990T3 (es) | 2012-10-12 | 2018-01-16 | Medimmune Limited | Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas |
| CN104837502B (zh) | 2012-10-12 | 2018-08-10 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
| DK2906298T3 (en) | 2012-10-12 | 2018-12-17 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| AU2013328625B2 (en) | 2012-10-12 | 2016-12-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| CN105189507A (zh) | 2012-12-21 | 2015-12-23 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
| SG11201507214SA (en) | 2013-03-13 | 2015-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| NZ710746A (en) | 2013-03-13 | 2018-11-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CA2905181C (en) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
| EP3033111B1 (en) | 2013-08-12 | 2019-03-13 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| KR20170042495A (ko) | 2013-12-16 | 2017-04-19 | 제넨테크, 인크. | 펩티드모방체 화합물 및 그의 항체-약물 접합체 |
| JP6671292B2 (ja) | 2013-12-16 | 2020-03-25 | ジェネンテック， インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
| BR112016013258A2 (pt) | 2013-12-16 | 2018-01-16 | Genentech Inc | composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit |
| JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| MX2017003123A (es) | 2014-09-12 | 2017-05-12 | Genentech Inc | Anticuerpos y conjugados modificados geneticamente con cisteina. |
| WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| US20160074527A1 (en) | 2014-09-17 | 2016-03-17 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
| AU2015352545B2 (en) | 2014-11-25 | 2020-10-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| MX2017007169A (es) | 2014-12-03 | 2018-05-02 | Genentech Inc | Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos. |
| US10441649B2 (en) | 2015-02-02 | 2019-10-15 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| EP3325005A4 (en) * | 2015-07-17 | 2019-03-27 | Brian J. Czerniecki | IDENTIFICATION OF IMMUNOGENIC MHC CLASS II PEPTIDES FOR IMMUNO-BASED THERAPY |
| CA2996902C (en) | 2015-10-02 | 2020-06-02 | Genentech, Inc. | Pyrrolobenzodiazepine antibody drug conjugates and methods of use |
| EP3362100B1 (en) | 2015-10-16 | 2022-06-22 | Genentech, Inc. | Hindered disulfide drug conjugates |
| EP3365025B1 (en) | 2015-10-20 | 2020-07-15 | Genentech, Inc. | Calicheamicin-antibody-drug conjugates and methods of use |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
| EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| US10639378B2 (en) | 2016-06-06 | 2020-05-05 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
| WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| MX375569B (es) | 2017-02-08 | 2025-03-04 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepinas y anticuerpos |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| PT3612537T (pt) | 2017-04-18 | 2022-08-29 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
| ES2977788T3 (es) | 2017-04-20 | 2024-08-30 | Adc Therapeutics Sa | Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco |
| MX2019015042A (es) | 2017-06-14 | 2020-08-06 | Adc Therapeutics Sa | Regimen de dosificacion. |
| DK3668874T3 (da) | 2017-08-18 | 2022-02-14 | Medimmune Ltd | Pyrrolobenzodiazepin-konjugater |
| IL273387B2 (en) | 2017-09-20 | 2023-10-01 | Ph Pharma Co Ltd | Thylanstatin analogs |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| BR112020025764A2 (pt) | 2018-06-19 | 2021-05-11 | Biontech Us Inc. | neoantígenos e usos dos mesmos |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| JP7708662B2 (ja) | 2018-10-24 | 2025-07-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | コンジュゲート化された化学的分解誘導物質および使用方法 |
| EP3894427A1 (en) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
| EP3894543A1 (en) * | 2018-12-14 | 2021-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| KR102890251B1 (ko) | 2019-03-15 | 2025-11-25 | 메드임뮨 리미티드 | 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트 |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| CN117980327A (zh) | 2021-11-03 | 2024-05-03 | 杭州多禧生物科技有限公司 | 抗体的特异性偶联 |
| AR128331A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpos y métodos de estos |
| AR128330A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpo y métodos de estos |
| EP4637833A2 (en) | 2022-12-23 | 2025-10-29 | Genentech, Inc. | Cereblon degrader conjugates, and uses thereof |
| EP4698230A2 (en) | 2023-04-17 | 2026-02-25 | Peak Bio, Inc. | Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates |
| WO2026006688A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Degrader antibody conjugates and uses thereof |
| WO2026006689A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Bcl-xl degrader antibody conjugates and uses thereof |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
| US5906980A (en) * | 1987-07-17 | 1999-05-25 | Hem Research Inc. | Treatment of hepatitis with mismatched dsRNA |
| US5683986A (en) * | 1987-08-12 | 1997-11-04 | Hemispherx Biopharma Inc. | Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment |
| US5593973A (en) * | 1987-09-04 | 1997-01-14 | Hemispherx Biopharma Inc. | Treatment of viral hepatitis with mismatched dsRNA |
| GB8725606D0 (en) * | 1987-11-02 | 1987-12-09 | Soc D Etudes Prod Chimique | Preparation polynucleotides |
| DE69023900T4 (de) * | 1989-02-24 | 1996-10-02 | The Regents Of The University Of California, Berkeley, Calif. | Gentechnologisch veränderte immunglobuline. |
| US5612035A (en) * | 1989-03-21 | 1997-03-18 | The Immune Response Corporation | Vaccination against diseases resulting from pathogenic responses by specific T cell populations |
| ZA908037B (en) * | 1989-10-11 | 1991-09-25 | Hem Res Inc | Protection from shock subsequent to injury by double-standed rnas |
| US5969109A (en) * | 1990-02-28 | 1999-10-19 | Bona; Constantin | Chimeric antibodies comprising antigen binding sites and B and T cell epitopes |
| US5998366A (en) * | 1990-09-21 | 1999-12-07 | The Regents Of The University Of California | Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders |
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US7252829B1 (en) * | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
| US5451273A (en) | 1992-12-01 | 1995-09-19 | Hydro-Petro Technology, Inc. | Cast alloy article and method of making and fuel filter |
| US5696109A (en) * | 1992-12-07 | 1997-12-09 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
| US5958457A (en) * | 1993-04-22 | 1999-09-28 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| JPH08510912A (ja) * | 1993-05-28 | 1996-11-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 遺伝子処理された免疫グロブリン |
| US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| BE1007823A3 (fr) * | 1993-12-10 | 1995-10-31 | Anda Biolog Sa | Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer. |
| WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| CA2194907A1 (en) * | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
| ATE509102T1 (de) * | 1994-07-15 | 2011-05-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5698679A (en) * | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
| US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| GB9501079D0 (en) * | 1995-01-19 | 1995-03-08 | Bioinvent Int Ab | Activation of T-cells |
| AU3583797A (en) * | 1996-06-28 | 1998-01-21 | Regents Of The University Of California, The | Enhancement of cancer cell death |
| WO1998036087A1 (en) | 1997-02-13 | 1998-08-20 | American National Red Cross | Immunological tolerance to hiv epitopes |
| US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| AU7690898A (en) * | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
| US6777546B2 (en) * | 1997-10-07 | 2004-08-17 | Loma Linda University | Methods and substances for preventing and treating autoimmune disease |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| RU2162687C2 (ru) * | 1998-02-03 | 2001-02-10 | Баринский Игорь Феликсович | Усовершенствованная лекарственная форма индуктора интерферона |
| WO1999054484A1 (en) * | 1998-04-20 | 1999-10-28 | The Regents Of The University Of California | Modified immunoglobulin molecules and methods for use thereof |
| US20020142974A1 (en) * | 1998-09-11 | 2002-10-03 | Leonard D. Kohn | Immune activation by double-stranded polynucleotides |
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
| EP1074617A3 (en) | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| JP4566494B2 (ja) * | 1999-11-02 | 2010-10-20 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | ＣｐＧレセプター（ＣｐＧ−Ｒ）およびＣｐＧ−Ｒに関する方法 |
| EP1286226B1 (en) * | 2000-05-25 | 2008-02-27 | Fuji Xerox Co., Ltd. | Toner and image forming method |
| AU2001264764A1 (en) * | 2000-05-31 | 2001-12-11 | Genzyme Corporation | Therapeutic anti-melanoma compounds |
| AU2001275294A1 (en) * | 2000-06-07 | 2001-12-17 | Biosynexus Incorporated. | Immunostimulatory RNA/DNA hybrid molecules |
| AU2001280934A1 (en) * | 2000-07-28 | 2002-02-13 | Alliance Pharmaceutical Corp. | Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds |
| US6811785B2 (en) * | 2001-05-07 | 2004-11-02 | Mount Sinai School Of Medicine Of New York University | Multivalent MHC class II—peptide chimeras |
| GB0119346D0 (en) | 2001-08-08 | 2001-10-03 | Bioclones Proprietary Ltd | Process for the maturation of dendritic cells |
| EP2258712A3 (en) | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
| JP2005526778A (ja) * | 2002-03-15 | 2005-09-08 | アストラル，インコーポレイテッド | 免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法 |
| JP2004016021A (ja) | 2002-06-12 | 2004-01-22 | Japan Science & Technology Corp | 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット |
| US20060172959A1 (en) * | 2003-03-26 | 2006-08-03 | Dan Smith | Selected rna motifs to include cell death and/or apoptosis |
| ATE511859T1 (de) * | 2004-07-20 | 2011-06-15 | Schering Corp | Apoptoseinduktion in toll-artige rezeptoren exprimierenden tumorzellen |
| CA2587676A1 (en) * | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
-
2003
- 2003-03-14 EP EP10182423A patent/EP2258712A3/en not_active Withdrawn
- 2003-09-18 AT AT03797931T patent/ATE460944T1/de not_active IP Right Cessation
- 2003-09-18 WO PCT/US2003/030188 patent/WO2004027049A2/en not_active Ceased
- 2003-09-18 CN CNA038252988A patent/CN1703427A/zh active Pending
- 2003-09-18 AU AU2003276932A patent/AU2003276932A1/en not_active Abandoned
- 2003-09-18 CA CA002499066A patent/CA2499066A1/en not_active Abandoned
- 2003-09-18 EP EP03797931A patent/EP1539819B1/en not_active Expired - Lifetime
- 2003-09-18 JP JP2004538491A patent/JP2006514920A/ja active Pending
- 2003-09-18 DE DE60331741T patent/DE60331741D1/de not_active Expired - Lifetime
- 2003-09-18 US US10/527,931 patent/US20060193855A1/en not_active Abandoned
-
2011
- 2011-04-01 US US13/078,119 patent/US8809290B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514920A5 (https=) | ||
| Crews et al. | Prophylactic cancer vaccines engineered to elicit specific adaptive immune response | |
| Cunningham et al. | Vaccine development: From concept to early clinical testing | |
| Lin et al. | Calcium phosphate nanoparticles as a new generation vaccine adjuvant | |
| Walayat et al. | Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine | |
| Kumai et al. | Cancer immunotherapy: moving forward with peptide T cell vaccines | |
| WO2004027049B1 (en) | Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells | |
| Melief et al. | Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines | |
| ES2883343T3 (es) | Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos | |
| JP2013543855A5 (https=) | ||
| JP2011519869A5 (https=) | ||
| JP2009515831A5 (https=) | ||
| JP2005507388A5 (https=) | ||
| Xiang et al. | Promising particle-based vaccines in cancer therapy | |
| JP2009525260A5 (https=) | ||
| JP2018509163A5 (https=) | ||
| Mohammed et al. | Cancer vaccines: past, present, and future | |
| JP2008508313A5 (https=) | ||
| JP2018536002A5 (https=) | ||
| Jin et al. | Soft matter DNA nanoparticles hybridized with CpG motifs and peptide nucleic acids enable immunological treatment of cancer | |
| JP2002531521A5 (https=) | ||
| JP2012021028A5 (https=) | ||
| Floudas et al. | Immunotherapy: current status and future perspectives | |
| He et al. | Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects | |
| JP2010508857A5 (https=) |